Supplementary Materials:

Expansion of Circulating Tumor Cells from Patients with Locally Advanced Pancreatic Cancer Enable Patient Derived Xenografts and Functional Studies for Personalized Medicine

Lianette Rivera-Báez, Ines Lohse, Eric Lin, Shreya Raghavan, Sarah Owen, Ramdane Harouaka, Kirk Herman, Geeta Mehta, Theodore S. Lawrence, Meredith A. Morgan, Kyle C. Cuneo and Sunitha Nagrath

Table 1. Pancreatic cancer patient characteristics.

| Patient	Sex	Age	Diagnosis	Stage	CTC Number/mL	EMT-Like CTC/mL	Epithelial-Like CTC/mL
P.1*	m[#]	53	PDAC[$]	T4N0M0**	14	11	3
P.2*	f[##]	74	PDAC	T4N0M0	44	44	0
P.3*	f	54	PDAC	T4N0M0	20	16	4
P.4	m	64	PDAC	T4N0M0	10	6	4
P.5	m	53	PDAC	T4N0M0	21	11	9
P.6	f	73	PDAC	T4N0M0	7	7	0
P.7	f	60	PDAC	T3N0M0	19	17	2
P.8	f	69	PDAC	T4N0M0	49	49	0
P.9	m	61	PDAC	T4N0M0	8	6	2
P.10	f	50	PDAC	T4N0M0	51	45	6

* CTC cell lines were established for these patients, [#] male, [##] female, [$] pancreatic ductal adenocarcinoma, **TNM classification of tumors of the exocrine pancreas: T4, tumor extends directly into any of the following: stomach, spleen, colon, adjacent large vessels; N0, no regional lymph node metastasis; M0, no distant metastasis.

Table 2. CTC number and characteristics change in response to treatment.

Patient	Visit	Treatment	CTC Number/mL	EMT-Like CTC/mL	Epithelial-Like CTC/mL
P.1	V1	untreated	14	11	3
	V2	Gemcitabine, AZD1778	11	9	2
P.2	V1	untreated	44	44	0
	V2	Gemcitabine, AZD1778	3	3	0
P.4	V1	untreated	10	6	4
	V2	Gemcitabine, AZD1778	2	2	0

Table 3. CTC characteristics in CTC cultures.

Patient	Adherent Culture		Spheroid Culture	
	EMT-Like CTC (%)	Epithelial-Like CTC (%)	EMT-Like CTC (%)	Epithelial-Like CTC (%)
P.1	87%	13%	57%	43%
P.2	12%	88%	37%	63%
P.3	85%	15%	66%	34%

Figure 1. KRAS G12/G13 mutation detection in CTC-derived cell lines. Digital PCR plots of CTC-derived cell lines compared to control cell lines, with mutant (FAM) droplets (top) and wildtype (HEX) droplets (bottom) compared to droplet count. The corresponding KRAS G12/G13 mutation status is shown below.